177Lu-PSMA-DGUL / CellBion 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
177Lu-PSMA-DGUL / CellBion
NCT05547061: A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Recruiting
1/2
73
RoW
Lu-177-DGUL, Ga-68-NGUL
Cellbion Co., Ltd.
Prostate Cancer, mCRPC
12/24
12/24

Download Options